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Introduction
Schizophrenia is one of the most disabling and economically catastrophic disorders. According to the World Health Organization, it is one of the top ten illness contributing to the global burden of disease. 1 It is a chronic and debilitating condition where prompt and effective management is crucial in determining and mitigating the diverse and potentially profound consequences of the disorder.
Pharmacotherapy has been the primary treatment for schizophrenia, and antipsychotics are the first-line drugs used. They have been shown in clinical trials to be effective in treating symptoms and behaviors associated with the disorder. 2, 3 The introduction of chlorpromazine in the mid-20th century 4, 5 for the treatment of psychosis was a landmark in the management of schizophrenia and other related psychoses. Today, first-generation (FGA) and second-generation antipsychotics (SGA) are the groups of psychotropics used to treat schizophrenia. 6, 7 An unpredictable pattern has been observed in the prescription of antipsychotics and other psychotropic medications to patients with schizophrenia in clinical practice. In some parts of the world, there is a higher percentage of prescriptions of SGAs, [8] [9] [10] while in others, FGAs are preferably prescribed. [10] [11] [12] In Nigeria, oldgeneration antipsychotics were reported as the most commonly prescribed medications for the treatment of schizophrenia, both decades ago 13 and recently. 14 FGAs were also mostly used for the treatment of other psychotic disorders, 15 but olanzapine, an SGA, was found to be the most frequently prescribed antipsychotic in monotherapy in a recent study. 16 Antiparkinsonian drugs were often prescribed at the onset of treatment, 17 against side effects, without evidence that the latter would occur in the course of treatment. The choice of antipsychotics prescribed to a patient with schizophrenia has a significant relationship with the long-term outcome of the disorder. 18, 19 In this sense, it is extremely important to evaluate how accumulating knowledge and the emerging use of SGAs in some parts of the world influence prescriptions for schizophrenia in clinical practice over time in our setting. We speculate that in a teaching hospital, where future psychiatrists are trained, the pattern of prescriptions established for patients will ultimately influence the choices of medications that these physicians will prescribe post-training.
Therefore, this study sought to determine the psychotropic prescriptions given to patients with schizophrenia at the outpatient clinic of a tertiary teaching hospital in Nigeria. It describes choices and trends, and how they relate to other factors that may influence treatment outcomes.
Materials and methods
This was a retrospective (patient chart-based), There was a total of 234 initial prescriptions and 228 current prescriptions, with an average of 2.2 prescriptions per patient, consisting of two antipsychotics and an anticholinergic agent. All patients received trihexyphenidyl tablets. All the medications were taken orally (tablets), with the exception of fluphenazine and flupentixol, which were administered via parenteral route (injection).
Haloperidol was the most commonly prescribed drug to patients who had been admitted to hospital in the past (67.9%). Other FGAs (28.3%) were mostly prescribed for these groups of patients, rather than SGAs (3.8%) ( Figure 1 ).
Haloperidol (35.8%) and other FGAs (39.6%) were also the most commonly prescribed current medications to patients who had been admitted in the past, but there was an increase in the proportion of those who received SGAs (24.5%) ( Figure 2 ).
Similarly, haloperidol (52%) and other FGAs (46%)
were the most commonly prescribed initial drugs for the treatment of schizophrenia in non-hospitalized patients at their first presentation at the outpatient clinic, upon initiation of treatment ( Figure 3 ).
Haloperidol (30%) and other FGAs (50%) were the most commonly prescribed medications for the continuation of treatment in outpatients who had never been hospitalized.
SGAs were prescribed to a few patients (18%) ( Figure 4 ). of the patients. For those who had a note indicating why their drug type or class was changed, the main reasons included the presence of extrapyramidal side effects (51.3%). Other reasons were also given ( Figure 5 ). The age and sex of the respondents in this study were comparable to those reported by similar studies. 8, 9, 20, 21 About 70% of the patients were unemployed in this study. Some studies that determined the employment status of patients with schizophrenia who were on antipsychotics found that the majority of them were unemployed. 8, 9 Employment rates among patients with schizophrenia are low, with an estimate from a European study ranging from 8 to 35%. 22 Individual factors (such as job histories), illness-related factors (such as illness severity) and societal conditions (such as discrimination and social welfare policy) are all potential contributors to variations in employment rates. 23 Haloperidol, an FGA, was found to be the most commonly prescribed medication across all categories, while olanzapine was the preferred SGA. 12, 24, 25 The efficacy of FGAs in reducing positive symptoms is not in doubt, 26, 27 but their action is quite limited in other outcomes, 28 notably, their effect on negative symptoms. The side effects of haloperidol and other FGAs constitutes a major problem in the pharmacotherapy of schizophrenia. 29 This has largely contributed to the search and emergence of SGAs -over the years, these drugs have been increasingly preferred over FGAs. In clinical practice, there has been a growing pattern of prescription of SGAs to patients with schizophrenia. 30 It was first believed that they were far superior to FGAs. However, that optimism was short-lived, as new findings suggest that SGAs may not have clear superior efficacy or better tolerability compared with FGAs. 6 to the newer medications. 33 In addition, another report has noted that there is no clear evidence that SGAs are more effective or better tolerated than FGAs. 34 Those authors concluded that FGAs should be used in the initial treatment of an episode of schizophrenia, unless the patient has not previously responded to these drugs or has unacceptable extrapyramidal side effects. 34 In developing countries such as Nigeria, or in resource-scarce settings, there is likely going to be an increasing use of FGAs and a slow transition to SGAs, largely as a result of the relatively higher cost of SGAs.
These drugs are often not within the reach of patients in our setting in a sustainable manner. The socioeconomic status of patients influences clinical management decisions. 35 positive and cognitive symptoms. 37 In addition, they may increase the risk for other medical disorders 38 and can affect the patients' quality of life and willingness to take the medication. 36, 39 Whether SGAs have fewer and more tolerable side effects than FGAs is still contentious. Studies have reported that there are no significant differences between SGAs and perphenazine, a representative FGA. 32, 40 Following recent advances on what is known about both classes of antipsychotics, the role of SGAs in the management of schizophrenia is a pressing clinical uncertainty. 34 Most patients with schizophrenia are currently receiving SGAs, particularly olanzapine, as the primary treatment. There has been a growing pattern in their use, 30 even for off-label purposes, 41 supported by research evidence, 42 national policies and marketing campaigns. 43 There are also treatment guidelines in some countries which recommend SGAs over FGAs. 9, 44 To what extent SGAs have a clear advantage over FGAs is still a subject of debate.
It is interesting to note that no prescription of clozapine was found in this study. At present, clozapine, an SGA, is reserved for the management of difficult-to treat schizophrenia. This may be a conservative approach by physicians to avoid the plethora of adverse effects and routine investigations associated with the use of that drug, or may result from the fact that patients clearly cannot afford the drug. Of note, also, is the record that all patients were on anticholinergic drugs, apparently to treat or prevent some side effects of antipsychotics.
This included patients who were admitted to hospital, i.e., who could be watched and managed for such side effects if and when they occurred. Certainly not all patients require this additional pill burden, which is often given perpetually. This practice of prescribing anticholinergics to all patients on antipsychotics may be regarded as polypharmacy.
Limitations
This study relied on data recorded on patient charts.
Additional interviews with the physicians and patients to inquire about their perspectives on prescription choices and treatment outcomes, respectively, would have enriched the quality of results. Secondly, the study was conducted at one center only, so the findings may not be applicable to other tertiary psychiatric facilities.
Conclusion
The prescription and use of safe, affordable and available antipsychotics in patients with schizophrenia will continue to be a major factor in determining the outcome of the disorder. While there are treatment guidelines to follow in some countries, no recommendations are available in others -including
Nigeria. If this study is a modest reflection of the practice of clinics operating in other socioeconomically comparable nations, we do not see predictable changes in the pattern of psychotropic prescriptions to patients with schizophrenia occurring soon. Therefore, it is likely that the decisions on what medications prescribers give to these patients will continue to be highly determined by the individual physicians' experience, personal choices and whatever factors he/she has judged to be clinically relevant.
